ANI Pharmaceuticals, Inc.
ANIP
$76.53
$0.430.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 883.37M | 826.88M | 747.40M | 674.07M | 614.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 883.37M | 826.88M | 747.40M | 674.07M | 614.38M |
| Cost of Revenue | 341.31M | 324.55M | 294.23M | 274.09M | 250.21M |
| Gross Profit | 542.06M | 502.34M | 453.17M | 399.98M | 364.17M |
| SG&A Expenses | 315.75M | 298.27M | 291.29M | 259.14M | 231.54M |
| Depreciation & Amortization | 91.42M | 91.40M | 84.52M | 75.94M | 67.73M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 800.14M | 770.27M | 723.92M | 653.80M | 594.06M |
| Operating Income | 83.23M | 56.61M | 23.48M | 20.27M | 20.32M |
| Income Before Tax | 95.79M | 50.55M | -14.75M | -27.56M | -22.21M |
| Income Tax Expenses | 17.45M | 9.98M | -4.54M | -6.51M | -3.69M |
| Earnings from Continuing Operations | 78.34 | 40.57 | -10.21 | -21.05 | -18.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 78.34M | 40.57M | -10.21M | -21.05M | -18.52M |
| EBIT | 83.23M | 56.61M | 23.48M | 20.27M | 20.32M |
| EBITDA | 174.65M | 148.01M | 108.00M | 96.20M | 88.05M |
| EPS Basic | 3.48 | 1.70 | -0.75 | -1.16 | -1.02 |
| Normalized Basic EPS | 2.01 | 1.09 | 0.06 | -0.07 | -0.04 |
| EPS Diluted | 3.35 | 1.63 | -0.77 | -1.18 | -1.04 |
| Normalized Diluted EPS | 1.93 | 1.04 | 0.05 | -0.07 | -0.04 |
| Average Basic Shares Outstanding | 80.20M | 78.96M | 78.29M | 77.78M | 77.27M |
| Average Diluted Shares Outstanding | 83.22M | 80.89M | 79.20M | 78.22M | 77.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.48% | 3.85% | -15.91% | -7.72% | -8.77% |